Rapport Therapeutics

RAPP

Market cap $1.42B

The consensus price target hints at a 75% upside potential for Rapport Therapeutics, Inc. (RAPP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5–9, 2025, in Atlanta. The Company will present during the meeting's poster sessions and will also host a dedicated Scientific Exhibit Room highlighting the RAP-219 clinical program.

The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures  Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027 Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public offering Ended the quarter with $513.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the third quarter ending September 30, 2025, and provided a business update. “The positive Phase 2a results for RAP-219 announced in September underscore both the strength of our precision neuroscience platform and the compound's differentiated clinical potential,” said Abraham N.

BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Stifel 2025 Healthcare Conference (New York City, NY) – fireside chat on Thursday, November 13, 2025, at 1:20-1:50pm ET. Jefferies Global Healthcare Conference (London, UK) – fireside chat on Monday, November 17, 2025, at 1:00-1:25pm GMT/8:00-8:25am ET.

The volatile sector is seeing greater stability, and these four stocks can profit.

SAN FRANCISCO & AUSTIN, Texas & EDINBURGH, Scotland--(BUSINESS WIRE)-- #AI--Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation.

Rapport Therapeutics, Inc. (NASDAQ:RAPP ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT Company Participants Abraham Ceesay - CEO, President, Treasurer & Director Troy Ignelzi - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Hi, everyone, and thank you for joining us at our 2025 Fifth Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Crédit Agricole Normandie Seine : Rapport financier semestriel 2025 Le rapport financier semestriel au 30/06/2025 de la Caisse régionale de Crédit Agricole Mutuel Normandie Seine a été déposé auprès de l'Autorité des Marchés Financiers (AMF). Ce rapport comprend les éléments suivants : Examen de la situation financière et résultats Informations prudentielles et facteurs de risques Présentation des comptes consolidés Rapport des Commissaires aux Comptes sur les comptes consolidés Attestation du responsable de l'information financière Ce document en version française est consultable sur le site Internet du Crédit Agricole Normandie Seine : rubrique "Informations réglementées" ou sur le lien suivant : https://www.credit-agricole.fr/ca-normandie-seine/particulier/informations/informations-reglementees-maj.html Attachment 04.C1 - CR883 - Rapport Word - Groupe C Semestriel_Vdef